Outset Medical, Inc. (OM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.30%. A quarter ago, it was expected that this company would post a loss of $0.53 per share when it actually produced a loss of $0.57, delivering a surprise of -7.55%. Over the last four quarters, the company has sur ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | Forward-looking statements and non-GAAP information | --- | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-0514392 (State or other jurisdiction ...

Exhibit 99.1 Outset Medical Reports Second Quarter 2024 Financial Results San Jose, CA – August 7, 2024 – Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2024. "During the quarter, the number of treatments performed each month on Tablo continued at record levels, as utilization remained high and gross margi ...

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Revenues are expected to be $31.19 million, down 13.5% from the year-ago quarter. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. The Zacks Earnings ESP compares the ...

Outset Medical, Inc. (OM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Most Powerful Force Impacting Stock Prices The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressiv ...

Outset Medical, Inc. (NASDAQ:OM) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Jim Mazzola - Head, IR Leslie Trigg - Chair & CEO Nabeel Ahmed - CFO Conference Call Participants Rick Wise - Stifel Shagun Sing - RBC Capital Markets Marie Thibault - BTIG Kristen Stewart - CL King Suraj Kalia - Oppenheimer Stephanie Piazzola - Bank of America Securities Joshua Jennings - TD Cowen Operator Good day and thank you for standing by. Welcome to the Outset Medical Q1 2024 Earnings Confer ...

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.55%. A quarter ago, it was expected that this company would post a loss of $0.61 per share when it actually produced a loss of $0.59, delivering a surprise of 3.28%.Over the last four quarters, the company has surpas ...

Outset Medical, Inc. (NASDAQ:OM) Q4 2023 Earnings Conference Call February 21, 2024 5:00 PM ET Company Participants Jim Mazzola - VP, IR Leslie Trigg - Chair & CEO Nabeel Ahmed - CFO Conference Call Participants Rick Wise - Stifel Kristen Stewart - CL King Andrew Ranieri - Morgan Stanley Shagun Singh - RBC Capital Markets Joshua Jennings - TD Cowen Operator Thank you for standing by, and welcome to the Outset Medical Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a liste ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-0514392 Washington, D.C. 20549 (State or other jurisdiction of ...